Medtronic plc (NYSE: MDT), a leader in healthcare technology, announced breakthrough results at the Heart Rhythm Society (HRS) 2024 Annual Meeting for its Affera Mapping and Ablation System with Sphere-9 Catheter. This system, designed for the treatment of persistent atrial fibrillation (AFib), has demonstrated significant safety and efficacy in the SPHERE Per-AF study, a pivotal […]
Viz.ai, an artificial intelligence (AI) powered health technology company, has signed a multi-year agreement with Bristol Myers Squibb (BMY) to provide the latter with an AI algorithm and provider workflow software called Viz HCM. The AI algorithm and the Viz HCM software are intended to be used by Bristol Myers Squibb for identifying and triaging […]
Zydus Lifesciences has bagged final approval from the US Food and Drug Administration (FDA) for Apixaban Tablets, 2.5mg and 5mg, a generic version of Eliquis Tablets. Apixaban inhibits the activity of certain clotting compounds in the blood. It reduces the chance of suffering from stroke or blood clots in patients with a heart rhythm disorder […]
Adagio Medical, a California-based medical device company focused on developing treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), has raised $42.5 million in a Series E equity financing round. The company has also developed the intelligent Continuous Lesion Ablation System (iCLAS). Its Series E financing round included new investors ArrowMark Partners, Perceptive Advisors, and […]
Abbott has been granted approval from the US Food and Drug Administration (FDA) for the CATALYST clinical trial to assess its Amplatzer Amulet Left Atrial Appendage Occluder for people with atrial fibrillation (AF). According to the US medical device company, the CATALYST trial is the first-ever clinical trial that will compare the effectiveness of a […]
Micro Labs and Mylan Pharmaceuticals have secured approval from the US Food and Drug Administration (FDA) for two applications for the first generics of Eliquis (apixaban) tablets to cut down the risk of stroke and systemic embolism in patients having nonvalvular atrial fibrillation. Apixaban is also indicated for the preventive treatment of deep vein thrombosis […]
Correvio Pharma said that the US Food and Drug Administration (FDA) decided not to approve its anti-arrhythmic drug Brinavess (vernakalant IV). In this connection, the Canadian specialty pharma company has been issued a complete response letter (CRL) from the FDA stating that it cannot approve the new drug application (NDA) for Brinavess in its present […]
Boston Scientific has announced that its LUMINIZE Radiofrequency (RF) Balloon Catheter, developed for isolating pulmonary veins (PVs) in atrial fibrillation (AF) treatment, has demonstrated positive safety and efficacy results in the AF-FICIENT I clinical trial. This new device marks an advancement in cardiac ablation technology and its ability to enhance treatment outcomes for patients with […]